Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: A multicentre phase II trial

European Journal of Cancer

Volumn 40, Issue 16, 2004, Pages 2424-2431

  Gridelli, C ^a   Manegold, C ^b   Mali, P ^c   Reck, M ^d   Portalone, L ^e   Castelnau, O ^f   Stahel, R ^g   Betticher, D ^h   Pless, M ⁱ   Pons, J Terrassa ^j   Aubert, D ^k   Burillon, J P ^k   Parlier, Y ^k   De Marinis, F ^e  

^a S G MOSCATI HOSPITAL   (Italy)

^b Thoraxklinik   (Germany)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f INSTITUT ARNAULT TZANCK   (France)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ KANTONSSPITAL   (Switzerland)

^j HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^k INSTITUT DE RECHERCHE PIERRE FABRE   (France)

more..

Author keywords

Advanced NSCLC; Elderly patients; Oral chemotherapy; Vinorelbine

Indexed keywords

NAVELBINE;

AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GERIATRICS; HUMAN; INFORMATION PROCESSING; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERCEPTION DEAFNESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 7044240643     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.028     Document Type: Article

References (22)

1. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 2002 92 98
2. T. LeChevalier, D. Brisgand, and J.Y. Douillard Randomised study of Navelbine and cisplatin versus vindesine and cisplatin versus Navelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients J Clin Oncol 12 1994 360 367
3. K. Kelly, J. Crowley, and P.A. Bunn Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a SouthWest Oncology Group trial J Clin Oncol 19 2001 3210 3218
4. C. Gridelli, C. Gallo, and F.A. Shepherd Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National cancer institute of Canada clinical trials group J Clin Oncol 21 2003 3025 3034
5. M. Marty, P. Fumoleau, and A. Adenis Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumours Ann Oncol 12 11 2001 1643 1649
6. J. Jassem, R. Ramlau, and H. Karnika-Modkowska A multicenter randomized Phase II study of oral vs. intravenous vinorelbine in advanced non-small cell lung cancer patients Ann Oncol 12 2001 1375 1381
7. G. Liu, E. Franssen, M.I. Fitch, and E. Warner Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1 1997 110 115
8. R. Yancik Cancer burden in the aged. An epidemiologic and demographic overview Cancer 80 7 1997 1273 1283
9. C. Gridelli, and F. Perrone Multicenter Italian lung cancer study in the elderly (MILES), Phase III randomized trial, chemotherapy for elderly patients with advanced non-small cell lung cancer J Natl Cancer Inst 95 5 2003 362 372
10. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999, 91(1), 66-72
11. P.A. Pizzo Management of fever in patients with cancer and treatment-induced neutropenia N Engl J Med 328 1993 1323 1332
12. P.J. Souquet, E.H. Tan, and J. Rodrigues Pereira GLOB 1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients Ann Oncol 13 2002 1853 1861
13. T.R. Fleming One-sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
14. P. Variol, L. Nguyen, B. Tranchand, and C. Puozzo A simultaneous oral/i.v. population pharmacokinetic model for vinorelbine Eur J Clin Pharmacol 58 2002 467 476
15. J.C. Van Heugen, J. De Graeve, G. Zorza, and C. Puozzo New sensitive liquid chromatography method coupled with tandem mass spectrometric detection or the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces J Chromatogr 926 2001 11 20
16. J. Bonneterre, B. Chevalier, and C. Focan Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC) Ann Oncol 12 12 2001 1683 1691
17. R. Bugat, P. Variol, H. Roché, P. Fumoleau, G. Robinet, and I. Senac The effects of food on the pharmacokinetic profile of oral vinorelbine Cancer Chemoth Pharmacol 50 2002 285 290
18. C. Puozzo, and C. Gridelli Non-small cell lung cancer in elderly patients: influence of age on Navelbine® oral pharmacokinetics Clinic Lung Cancer 5 2004 237 242
19. M. Weinmann, B. Jeremic, H. Toomes, G. Friedel, and M. Bamberg Treatment of lung cancer in the elderly Part I: non-small cell lung cancer Lung Cancer 39 2003 233 253
20. C.C. Earle, L.N. Venditi, and P.J. Neumann Who gets chemotherapy for metastatic lung cancer Chest 117 2000 1239 1246
21. C. Gridelli, Y. Parlier, and M. Brandely Oral chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea and vomiting in non-small cell lung cancer (NSCLC) patients (pts) treated with oral Navelbine (NVB) and standard antiemetic prophylaxis Eur J Cancer 1 5 2003 S244
22. A. Kanard, A. Jatoi, and R. Castillo Oral Vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity Lung Cancer 43 2004 345 353